Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 55,886 |
|
|||||
| News | - | ||||||
| Day High | 1.43 | Low High |
|||||
| Day Low | 1.25 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Petros Pharmaceuticals Inc | PTPI | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.05 | -3.62% | 1.33 | 12:14:12 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.34 | 1.25 | 1.43 | 1.38 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 327 | 55,886 | US$ 1.34 | US$ 74,755 | - | 0.9172 - 9.54 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 12:14:12 | 18 | US$ 1.33 | USD |
Petros Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.97M | 2.20M | - | 9.38M | -20.04M | -9.10 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Petros Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/30/2023 | 15:07 | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders |
| 11/30/2023 | 15:05 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 11/15/2023 | 16:11 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/15/2023 | 16:00 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
| 10/02/2023 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/19/2023 | 15:36 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 9/15/2023 | 16:16 | Edgar (US Regulatory) | Form S-3/A - Registration statement under Securities Act of.. |
| 9/15/2023 | 15:22 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/25/2023 | 16:08 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 8/15/2023 | 16:03 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/15/2023 | 16:01 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
| 8/14/2023 | 16:03 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PTPI Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.43 | 1.63 | 1.25 | 1.36 | 254,805 | -0.10 | -6.99% |
| 1 Month | 1.28 | 2.00 | 1.20 | 1.46 | 155,971 | 0.05 | 3.91% |
| 3 Months | 1.80 | 2.13 | 1.20 | 1.54 | 80,998 | -0.47 | -26.11% |
| 6 Months | 2.15 | 4.74 | 1.20 | 3.32 | 219,871 | -0.82 | -38.14% |
| 1 Year | 2.40 | 9.54 | 0.9172 | 4.73 | 779,381 | -1.07 | -44.58% |
| 3 Years | 35.20 | 59.599 | 0.9172 | 26.53 | 2,078,136 | -33.87 | -96.22% |
| 5 Years | 18.00 | 59.599 | 0.9172 | 26.54 | 2,059,557 | -16.67 | -92.61% |
Petros Pharmaceuticals Description
| Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Prescription Medications segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease. |
